{
    "nctId": "NCT00674414",
    "briefTitle": "Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery",
    "officialTitle": "A Phase II, Randomized, Multi-center Study, Assessing Value of Adding Everolimus (RAD001) to Trastuzumab as Preoperative Therapy of HER-2 Positive Primary Breast Cancer Amenable to Surgery.",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 82,
    "primaryOutcomeMeasure": "Efficacy as measured by clinical and echographic tumor evaluation",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed diagnosis of invasive breast cancer\n\n  * Previously untreated disease\n* Candidate for breast-conserving surgery, as defined by both of the following:\n\n  * Clinical stage cT1-3, cN0-2 disease\n  * Clinical stage M0 disease (bone scan, chest X-ray, and liver ultrasound required at screening to exclude metastatic disease)\n* HER2-positive primary tumor, defined as meeting either of the following criteria:\n\n  * IHC 3+\n  * IHC 2+ and FISH positive (centralized confirmation)\n* No inflammatory breast cancer or bilateral breast cancer\n\n  * Patients who have been treated for cancer of the contralateral breast can be included if there is at least a 5 year time interval from last systemic treatment for breast cancer before randomization into this study\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* WHO performance status 0-1\n* Menopausal status not specified\n* WBC \u2265 3.5 x 10\\^9/L\n* ANC \u2265 1.5 x 10\\^9/L\n* Platelet count \u2265 100 x 10\\^9/L\n* Hb \u2265 10 g/dL\n* Serum bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* Serum transaminases activity \u2264 2.5 times ULN\n* Alkaline phosphatase \u2264 2.5 times ULN\n* Creatinine \u2264 1.5 mg/dL OR creatinine clearance \u2265 60 mL/min\n* FEV \\> 55% by MUGA or ECHO\n* Spirometry and DLCO \\> 50% of normal\n* O_2 saturation \\> 88% at rest on room air\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No known hypersensitivity to everolimus, sirolimus, trastuzumab (Herceptin\u00ae), or lactulose\n* No hypercholesterolemia/hypertriglyceridemia \u2265 grade 3\n\n  * No hypercholesterolemia/hypertriglyceridemia \u2265 grade 2 with history of coronary artery disease (despite lipid-lowering treatment if given)\n* No uncontrolled infection\n* No other concurrent severe and/or uncontrolled medical disease which could compromise participation in the study, including any of the following:\n\n  * Uncontrolled hypertension\n  * Congestive cardiac failure\n  * Ventricular arrhythmias\n  * Active ischemic heart disease\n  * Myocardial infarction within the past year\n  * Chronic liver or renal disease\n  * Active gastrointestinal tract ulceration\n  * Severely impaired lung function\n* No known history of HIV seropositivity\n* No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule\n* Willing to participate in the biological investigations\n* Not deprived of liberty or placed under guardianship\n* Patients must be affiliated to a Social Security System\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* More than 30 days (from the screening visit) since prior other investigational drugs\n* More than 5 days (from randomization) since prior and no concurrent strong inhibitors or inducers of the isoenzyme CYP3A, including any of the following\n\n  * Rifabutin\n  * Rifampicin\n  * Clarithromycin\n  * Ketoconazole\n  * Itraconazole\n  * Voriconazole\n  * Ritonavir\n  * Telithromycin\n* No other concurrent anti-cancer treatments such as chemotherapy, immunotherapy/biological response modifiers, endocrine therapy, or radiotherapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}